Boeckhaus J, Tönshoff B, Weber LT, Haffner D, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Kettwig M, König S, John-Kroegel U, Gellermann J, Galiano M, Hafke A, Streit F, Gross O (2025)
Publication Type: Journal article
Publication year: 2025
DOI: 10.1007/s00467-025-07053-0
Background: Kidney failure (KF) in children and adolescents leads to reduced lifespan and compromised health. Alport syndrome (AS) is a leading hereditary cause of KF in children. Angiotensin-converting enzyme inhibitors (ACEi) have demonstrated efficacy in delaying KF in young people living with AS, but non-adherence can compromise their therapeutic benefits. To investigate the adherence to ACEi in children and adolescents with AS, a liquid chromatography-mass spectrometry (LCMS)-based method was developed for objective verification of recent medication intake at two different time points in this cohort study. Methods: Urine samples from 58 children enrolled in the EARLY PRO-TECT Alport trial were analyzed. An LCMS-based method was established and validated to simultaneously screen and quantify both ramipril and ramiprilat in urine samples. Participants were not informed in advance of the medication intake measurements. Results: A total of 106 urine samples from 58 patients with early stages of chronic kidney disease (mean estimated glomerular filtration rate, 130 ± 32 mL/min/1.73 m2) were analyzed at two different time points. All 13 negative control samples (100%; 95% confidence intervals [CI] 75.7% to 100%) were identified correctly. Adherence to ACEi at the time of sampling was consistently high, with 96% (47/49; 95% CI 86% to 99.5%) and 95% (42/44; 95% CI 84.5% to 99.4%) of children showing confirmed drug intake at initial and second adherence measurements. Conclusion: This study demonstrated that children with chronic kidney disease, when treated with ACEi within a clinical trial, show high adherence to the prescribed medication.
APA:
Boeckhaus, J., Tönshoff, B., Weber, L.T., Haffner, D., Pape, L., Latta, K.,... Gross, O. (2025). High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometry. Pediatric Nephrology. https://doi.org/10.1007/s00467-025-07053-0
MLA:
Boeckhaus, Jan, et al. "High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometry." Pediatric Nephrology (2025).
BibTeX: Download